This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Systematic search conducted without language restrictions from December 1, 2019 to June 31, 2022 on PubMed, EMBASE, Web of Science, Cochrane library, ProQuest Coronavirus Research Database, COVID-19 Living Overview of the Evidence (L-OVE) subset of Episteminokos and the World Health Organization (WHO) Covid-19 databases.
Background D-Dimer testing is a diagnostic tool for exclusion of deep vein thrombosis (DVT) and pulmonary embolism (PE). Methods In this prospective, observational, multicenter study (July 2017–August 2019), plasma samples were collected from hospital emergency departments and specialist referral centers.
Background:Coronavirus disease 2019 (COVID-19) increases the risk of cerebral venous sinus thrombosis (CVST), and previous reports derived from small case series reported a high mortality in these patients, up to 40%. Stroke, Volume 55, Issue Suppl_1 , Page ATP180-ATP180, February 1, 2024.
Researchers analyze primary and secondary cardiovascular outcomes in 132,784 inpatients with COVID-19 (October 8, 2020 to September 30, 2021) and 31,173 inpatients with non-COVID-19 pneumonia (January 1, 2019 to December 31, 2019) in Korea. The results indicate a lower risk of cardiovascular disease in COVID-19 patients.
Introduction:The majority of patients with cerebral venous thrombosis (CVT) achieve functional independence (modified Rankin Score [mRS] 0-2), although many continue to experience residual symptoms that negatively impact quality of life. Stroke, Volume 56, Issue Suppl_1 , Page AWP143-AWP143, February 1, 2025.
Background:Cerebral venous thrombosis (CVT) is associated with significant risk of death and disability. To prevent potential confounding by undiagnosed COVID-19, patients in 2019 were not utilized in the analysis. Stroke, Volume 55, Issue Suppl_1 , Page AWP260-AWP260, February 1, 2024.
MINOCA may be due to: coronary spasm, coronary microvascular dysfunction, plaque disruption, spontaneous coronary thrombosis/emboli , and coronary dissection; myocardial disorders, including myocarditis, takotsubo cardiomyopathy, and other cardiomyopathies. This is in spite of the known proclivity of tighter stenoses to thrombose.
Methods We retrospectively reviewed children with congenital heart diseases (CHDs) who received trans-axillary arterial catheterizations between January 2019 and February 2023. Background Axillary arterial access (AAA) in pediatric heart catheterizations is undervalued. We administrated intra-arterial verapamil (1.25 mg) min (IQR, 19.2–34.8).
The commonest causes of MINOCA include: atherosclerotic causes such as plaque rupture or erosion with spontaneous thrombolysis, and non-atherosclerotic causes such as coronary vasospasm (sometimes called variant angina or Prinzmetal's angina), coronary embolism or thrombosis, possibly microvascular dysfunction.
We examine variation in rates of MT by geographic region and urban-rural areas to identify utilization disparities across the United States.Methods:The state-specific annual incidence of AIS in 2019 was determined using data from the Global Burden of Disease Collaborative Network.
This study aims to investigate the incidence, complications, and outcomes of SAH patients who develop HIT.MethodsICD‐9‐CM and ICD‐10‐CM codes were used to query the National Inpatient Sample for patients with SAH between 2010 and 2019. Results76,387 patients were diagnosed with SAH between 2010 and 2019.
The primary endpoint was the net clinical benefit as a composite of all-cause death, myocardial infarction, definite or probable stent thrombosis, stroke, and major bleeding at 1 year after the index procedure in the intention-to-treat population. versus 3.4%; HR, 0.35 [95% CI, 0.20–0.61];P<0.001).Conclusions:This
We calculated odds ratios (OR) and 95% confidence intervals (95%CI) for development of VTE based off demographics and clinical characteristics. 11.73, p=<0.0001), craniotomy OR 4.635 (95% CI: 1.952-11.007, p=0.0005), and ICH score 2 OR 4.346 (95% CI: 1.784-10.587, p=0.002).Factors
7 The use of antiplatelet agents to prevent stent thrombosis, moderate- to high-dose statin therapy after acute coronary syndromes, or antihypertensive agents in asymptomatic patients may all be perceived by patients as not providing benefit because they may not feel the effects.8
The primary efficacy objective was to demonstrate superiority of PPA to reduce the primary efficacy end point of all-cause death, nonfatal myocardial infarction, nonfatal stroke, stent thrombosis (definite), or urgent revascularization (any vessel) within 30 days. to 1.57]).
12,16 In 2017, CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) provided proof-of-principle that inflammation inhibition in the absence of lipid lowering can significantly reduce cardiovascular event rates and helped to define the interleukin-1 (IL-1) to IL-6 to CRP pathway as a central target in CV disease.16 References: 1.
The World Health Organisation (WHO) formally proclaimed COVID-19, the illness spread by a zoonotic SARS-CoV-2, as a pandemic in March 2020, after it had started to spread in late 2019. Even though the pandemic is on the wane, new studies and evidence about it continue to emerge.
Further research and attention to this area are crucial for improving patient outcomes and guiding clinical interventions in this challenging condition.MethodsICD‐10‐CM codes were used to query the National Inpatient Sample (NIS) for patients with AIS between 2010 and 2019. Patients with AKI were on average older (63.29
A second 12 Lead ECG was recorded: This is a testament to the dynamic nature of coronary thrombosis and thrombolysis. The patient verbalized spontaneous improvement just before 324mg ASA administration. Here the ST segments are not so deep, nor are the T waves so wide and bulky, because of improved coronary flow at the level of the occlusion.
MINOCA may be due to: coronary spasm, coronary microvascular dysfunction, plaque disruption, spontaneous coronary thrombosis/emboli , and coronary dissection. link] We know that most type 1 acute MI due to plaque rupture and thrombosis occurs in lesions that are less than 50% (see Libby reference).
We who know ischemic ECGs know that really when T-wave inversion is specific for coronary thrombosis that it indicates reperfusion of the artery, not active occlusion. For examples of such exceptions — See My Comment in the January 9, 2019 — August 22, 2020 — and June 30, 2023 posts in Dr. Smith's ECG Blog ).
Microvascular dysfunction — cardiac vasculitis — intravascular thrombosis. The September 30, 2019 post in Dr. Smith’s ECG Blog — for an example of “MAT”, but without the tachycardia. Acute pulmonary embolus. ARDS ( A dult R espiratory D istress S yndrome ). SIRS ( S ystemic I nflammatory R esponse S yndrome ).
Am J Med 2019, 132(5):622-630. Now there is a paper published in 2019 that proves the point beyond doubt, though makes it clear that this pattern is associated with very high mortality. American Journal of Medicine 132(5):622-630; May 2019. J Electrocardiol 2013;46:240-8 2. Harhash AA, Huang JJ, Reddy S, et al.
This case provides a constellation view of the many sequelae associated with HCM – preexisting disparities of coronary perfusion due to endothelial remodeling, exacerbated diastolic dysfunction when volume depleted, conduction disorders in the diseased His-P system, and thrombosis from microvascular coronary disease. References Naidu, S.
Standardized stroke ratios (SSRs) were calculated to compare stroke trends among TAVR patients with an age- and sex-matched general population in Switzerland, as per the 2019 Global Burden of Disease study. Between February 2011 and June 2021, 11,957 consecutive TAVR patients (average age 81.8 ± 6.5 female) were included.
IntroductionCerebral venous thrombosis (CVT) is an uncommon form of stroke with relatively low mortality but higher incidence in younger adults.1–3 IntroductionCerebral venous thrombosis (CVT) is an uncommon form of stroke with relatively low mortality but higher incidence in younger adults.1–3 vs. 5.6%; p=0.176). no COVID 5.5% [4.6‐6.6];
Methods All ACS patients admitted to a tertiary care center intensive cardiac care unit (ICCU) between July 2019 and July 2023 were prospectively enrolled. The primary outcome was in-hospital mortality.
Introduction:Acute ischemic stroke (AIS) patients are prone to medical complications such as acute kidney injury (AKI), acute myocardial infarction (AMI), deep vein thrombosis (DVT), gastrointestinal bleeding (GIB), pneumonia, pulmonary embolism (PE), sepsis, and urinary tract infection (UTI). had AIS-HC, 2.3% had AIS-SC, and 1.6%
MethodsThe clinical data of 209 consecutive patients who underwent PCI through the BA at Fu Wai Hospital between September 2019 and June 2024 were retrospectively collected. In group I, the brachial sheath was removed 4h after the PCI procedure.
Angiography was technically challenging as the patient was receiving CPR, but the cardiologist suspected acute stent thrombosis and initiated cangrelor, although no repeat angiography was able to be obtained. During the resuscitation, she received amiodarone 450 mg IV, lidocaine 100 mg IV, and magnesium 6 g IV.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content